---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-10T23:22:09.420974'
end_time: '2026-02-10T23:27:28.385775'
duration_seconds: 318.97
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: CYCS
  gene_symbol: CYCS
  uniprot_accession: P99999
  protein_description: 'RecName: Full=Cytochrome c;'
  gene_info: Name=CYCS; Synonyms=CYC;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the cytochrome c family. .
  protein_domains: Cyt_c-like_dom. (IPR009056); Cyt_c-like_dom_sf. (IPR036909); Cyt_c_1A/1B.
    (IPR002327); Cytochrom_C (PF00034)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 16
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P99999
- **Protein Description:** RecName: Full=Cytochrome c;
- **Gene Information:** Name=CYCS; Synonyms=CYC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the cytochrome c family. .
- **Key Domains:** Cyt_c-like_dom. (IPR009056); Cyt_c-like_dom_sf. (IPR036909); Cyt_c_1A/1B. (IPR002327); Cytochrom_C (PF00034)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CYCS" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CYCS' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CYCS** (gene ID: CYCS, UniProt: P99999) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P99999
- **Protein Description:** RecName: Full=Cytochrome c;
- **Gene Information:** Name=CYCS; Synonyms=CYC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the cytochrome c family. .
- **Key Domains:** Cyt_c-like_dom. (IPR009056); Cyt_c-like_dom_sf. (IPR036909); Cyt_c_1A/1B. (IPR002327); Cytochrom_C (PF00034)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CYCS" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CYCS' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CYCS** (gene ID: CYCS, UniProt: P99999) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan status: We verified the target identity (CYCS; UniProt P99999) and proceeded to compile recent, authoritative evidence on function, localization, pathways, cardiolipin interactions, and clinical applications. Some 2023–2024 subtopics (e.g., human CYCS variant THC4 and quantitative biomarker statistics) were not captured in the retrieved literature; we therefore provide partial coverage for those items and indicate gaps.

Gene/protein identity verification and core definitions
- Identity and nomenclature: CYCS encodes human cytochrome c, a small heme c protein in the cytochrome c family that functions in mitochondrial respiration and intrinsic apoptosis. The retrieved 2024 review explicitly frames cytochrome c as the electron carrier of the respiratory chain and a central mediator of apoptosome formation with Apaf-1, consistent with the UniProt description and the cytochrome c-like domain architecture provided (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 1-2, alshehri2024cytochromecand pages 3-5).
- Primary molecular functions: (1) Electron transfer: cytochrome c shuttles electrons from complex III (cytochrome bc1) to complex IV (cytochrome c oxidase) in the inner mitochondrial membrane cristae region, supporting oxidative phosphorylation. (2) Apoptosis: upon mitochondrial outer membrane permeabilization (MOMP), cytochrome c is released into the cytosol where it binds Apaf-1 to assemble the apoptosome and activate caspase-9, leading to downstream effector caspase activation. Both roles are supported in 2024 synthesis and earlier canonical literature cited therein (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 3-5, alshehri2024cytochromecand pages 11-11, alshehri2024cytochromecand pages 11-12).

Subcellular localization and structural context
- Basal localization: cytochrome c is localized to the mitochondrial intermembrane space (IMS), associated with the inner mitochondrial membrane via electrostatic and hydrophobic interactions, including binding to cardiolipin-rich cristae surfaces. Its mobility enables rapid electron transfer between complex III and IV organized in respirasomes on cristae membranes (URL: https://doi.org/10.1038/s42255-023-00904-w; 2023-10; and https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (guhathakurta2023cox17acetylationvia pages 3-4, alshehri2024cytochromecand pages 1-2).
- Release during intrinsic apoptosis: following MOMP (BAX/BAK-dependent), cytochrome c translocates to the cytosol (and later can appear extracellularly), initiating apoptosome formation. Time-resolved release and cytosolic signaling are summarized in recent review material (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 3-5, alshehri2024cytochromecand pages 2-3).

Pathways and interactions
- Respiratory chain (ETC): cytochrome c mediates electron flow from complex III to complex IV in cristae, with complex IV integrity and cristae architecture tightly linked to OXPHOS efficiency. Recent 2023 work shows that perturbation of complex IV assembly (via impaired COX17 acetylation by the MOF–KANSL complex) compromises respiratory supercomplexes and cristae structure, thereby impacting the environment where cytochrome c operates (URL: https://doi.org/10.1038/s42255-023-00904-w; 2023-10) (guhathakurta2023cox17acetylationvia pages 3-4).
- Intrinsic apoptosis: cytosolic cytochrome c + Apaf-1 → apoptosome → caspase-9 activation → caspase-3/7. This central pathway is reiterated in 2024 synthesis and linked to historic mechanistic studies (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 11-11, alshehri2024cytochromecand pages 3-5, alshehri2024cytochromecand pages 11-12).

Cardiolipin interactions and peroxidase activity (recent insights)
- Mechanistic role of cardiolipin (CL): cytochrome c binds anionic cardiolipin on the inner mitochondrial membrane. Oxidative modification of CL reduces its affinity for cytochrome c and facilitates its detachment and release during apoptosis and neurotrauma. 2024 review summarizes lipidomic and injury-model evidence (TBI/SCI) showing CL loss/oxidation, concurrent cytosolic release of cytochrome c and caspase activation, and the potential of CL as a biomarker (URL: https://doi.org/10.3390/cells13070609; 2024-03-27) (fuentes2024theroleof pages 10-12).
- Peroxidase activity switch: the cytochrome c–cardiolipin complex acquires peroxidase-like activity that promotes CL oxidation, amplifying mitochondrial permeabilization and apoptosis. 2024 review notes that SS-31 (elamipretide), a CL-interacting tetrapeptide, “prevents the conversion of cytochrome c into a peroxidase,” highlighting a druggable aspect of this interaction (URL: https://doi.org/10.3390/cells13070609; 2024-03-27) (fuentes2024theroleof pages 10-12). Additional 2024 synthesis corroborates CL peroxidation as a release mechanism (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 3-5, alshehri2024cytochromecand pages 8-8).

Post-translational modifications (PTMs)
- Overview: Recent synthesis indicates that cytochrome c function is modulated by PTMs (e.g., phosphorylation, acetylation, and oxidative modifications), which can alter its redox properties, Apaf-1 interactions, and apoptogenic potential. Specific phosphorylation instances (e.g., threonine or tyrosine residues) have been linked to altered apoptotic signaling in prior literature summarized in 2024 review (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 11-11, alshehri2024cytochromecand pages 8-8).
- 2023–2024 mitochondrial acetylation landscape context: While not a PTM on cytochrome c itself, 2023 work revealed mitochondrial protein acetylation (MOF–KANSL-dependent) as a regulatory axis that maintains complex IV assembly and cristae integrity (via COX17 acetylation). This provides an updated framework for how respiratory chain context—and thus cytochrome c electron transfer—can be tuned by PTMs at the organelle level (URL: https://doi.org/10.1038/s42255-023-00904-w; 2023-10) (guhathakurta2023cox17acetylationvia pages 3-4).

Human disease associations and applications
- Broad disease relevance: Altered cytochrome c localization and abundance are reported across cancer and injury contexts. The 2024 synthesis notes reduced cytochrome c levels in multiple tumor tissues and dynamic increases in serum after therapy, consistent with apoptosis induction. It also catalogs reports of elevated circulating cytochrome c in inflammatory arthritis, myocardial infarction, and liver disease, and experimental cardioprotection by exogenous cytochrome c in septic models (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 8-8).
- Thrombocytopenia 4 (THC4; CYCS variants): We were unable to retrieve recent (2023–2024) human-primary literature explicitly detailing CYCS germline variants in THC4 within the current evidence set. THC4 is historically associated with gain-of-function apoptosis sensitization in megakaryocyte/platelet lineages due to CYCS mutations; however, we cannot cite 2023–2024 updates or case statistics from the sources retrieved here. This portion is therefore incomplete pending targeted retrieval (no source in current set).

Circulating cytochrome c as a biomarker (evidence and data)
- Concept and evidence: The 2024 review collates observations of circulating cytochrome c in human disease (e.g., after myocardial infarction and in inflammatory conditions) and its emergence as a prognostic/theranostic marker in oncology (post-chemotherapy increases correlating with tumor cell death) (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 8-8, alshehri2024cytochromecand pages 3-5).
- Quantitative statistics: Specific contemporary (2023–2024) AUCs, thresholds, or prognostic hazard ratios for sepsis, trauma, or cardiogenic shock were not available in the captured evidence. Accordingly, we refrain from quantitative claims and highlight this as a gap for future curation.

Expert perspectives and structural/pathway updates (2023–2024)
- Structure–function of the respiratory apparatus: 2023 mechanistic evidence shows mitochondrial acetylation by MOF–KANSL governs complex IV assembly and respirasome integrity, thereby shaping the cristae environment and electron-transfer landscape in which cytochrome c operates (URL: https://doi.org/10.1038/s42255-023-00904-w; 2023-10) (guhathakurta2023cox17acetylationvia pages 3-4).
- Apoptosome structural updates: The 2024 review references the classical Apaf-1–cytochrome c apoptosome paradigm but our retrieved set did not include the newest (2023–2024) high-resolution human apoptosome structures; thus, we provide pathway-level synthesis without structural novelties (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 11-11, alshehri2024cytochromecand pages 11-12).

Real-world implementations and therapeutics
- Mitochondria-targeted cardiolipin modulators: SS-31 (elamipretide) is highlighted as interacting with cardiolipin to prevent the peroxidase conversion of cytochrome c, a mechanism with translational promise in diseases characterized by CL oxidation and mitochondrial dysfunction (URL: https://doi.org/10.3390/cells13070609; 2024-03-27) (fuentes2024theroleof pages 10-12).
- Clinical and preclinical contexts: The 2024 synthesis points to use-cases where circulating cytochrome c informs on tissue injury and therapy response, and notes experimental administration of cytochrome c in septic models; these underscore biomarker and interventional possibilities that are currently condition- and study-specific (URL: https://doi.org/10.1016/j.jsps.2024.102194; 2024-12) (alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 8-8).

Selected data points from recent sources
- Cardiolipin loss/oxidation in injury: 2024 review summarizes SCI models with ~50% reductions in specific cardiolipin species concomitant with release of cytochrome c and caspase-3 activation, supporting the CL–cytochrome c peroxidase/release axis; precise species-level lipidomics and model details are compiled therein (URL: https://doi.org/10.3390/cells13070609; 2024-03-27) (fuentes2024theroleof pages 10-12).
- Mitochondrial architecture and ETC integrity: 2023 study shows loss of MOF–KANSL function reduces cardiolipin species, diminishes complex IV and respiratory supercomplexes, and increases mitochondrial ROS while fragmenting cristae—conditions that would impede efficient cytochrome c electron transfer (URL: https://doi.org/10.1038/s42255-023-00904-w; 2023-10) (guhathakurta2023cox17acetylationvia pages 3-4).

Conclusions
- CYCS encodes human cytochrome c, a dual-role protein indispensable for mitochondrial respiration and intrinsic apoptosis. 2023–2024 literature reinforces the centrality of cardiolipin–cytochrome c interactions and their peroxidase-driven remodeling in apoptosis and neurotrauma, and highlights organelle-level PTM regulation that shapes the respiratory environment. Circulating cytochrome c continues to emerge as a biomarker of cellular injury and therapy response. However, specific 2023–2024 updates on CYCS variant-associated thrombocytopenia (THC4) and rigorous quantitative biomarker statistics for sepsis/trauma/cardiogenic shock were not captured here and warrant targeted follow-up.

Cited sources (URLs and dates)
- Alshehri B. Cytochrome c and cancer cell metabolism: A new perspective. Saudi Pharmaceutical Journal. 2024-12. URL: https://doi.org/10.1016/j.jsps.2024.102194 (alshehri2024cytochromecand pages 1-2, alshehri2024cytochromecand pages 3-5, alshehri2024cytochromecand pages 2-3, alshehri2024cytochromecand pages 11-11, alshehri2024cytochromecand pages 8-8, alshehri2024cytochromecand pages 11-12)
- Guhathakurta S, Erdogdu NU, Hoffmann JJ, et al. COX17 acetylation via MOF–KANSL complex promotes mitochondrial integrity and function. Nature Metabolism. 2023-10. URL: https://doi.org/10.1038/s42255-023-00904-w (guhathakurta2023cox17acetylationvia pages 3-4)
- Fuentes JM, Morcillo P. The Role of Cardiolipin in Mitochondrial Function and Neurodegenerative Diseases. Cells. 2024-03-27. URL: https://doi.org/10.3390/cells13070609 (fuentes2024theroleof pages 10-12)

References

1. (alshehri2024cytochromecand pages 1-2): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

2. (alshehri2024cytochromecand pages 3-5): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

3. (alshehri2024cytochromecand pages 2-3): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

4. (alshehri2024cytochromecand pages 11-11): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

5. (alshehri2024cytochromecand pages 11-12): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

6. (guhathakurta2023cox17acetylationvia pages 3-4): Sukanya Guhathakurta, Niyazi Umut Erdogdu, Juliane J. Hoffmann, Iga Grzadzielewska, Alexander Schendzielorz, Janine Seyfferth, Christoph U. Mårtensson, Mauro Corrado, Adam Karoutas, Bettina Warscheid, Nikolaus Pfanner, Thomas Becker, and Asifa Akhtar. Cox17 acetylation via mof–kansl complex promotes mitochondrial integrity and function. Nature Metabolism, 5:1931-1952, Oct 2023. URL: https://doi.org/10.1038/s42255-023-00904-w, doi:10.1038/s42255-023-00904-w. This article has 29 citations and is from a domain leading peer-reviewed journal.

7. (fuentes2024theroleof pages 10-12): J. M. Fuentes and Patricia Morcillo. The role of cardiolipin in mitochondrial function and neurodegenerative diseases. Cells, 13:609, Mar 2024. URL: https://doi.org/10.3390/cells13070609, doi:10.3390/cells13070609. This article has 36 citations and is from a poor quality or predatory journal.

8. (alshehri2024cytochromecand pages 8-8): Bader Alshehri. Cytochrome c and cancer cell metabolism: a new perspective. Saudi Pharmaceutical Journal, 32:102194, Dec 2024. URL: https://doi.org/10.1016/j.jsps.2024.102194, doi:10.1016/j.jsps.2024.102194. This article has 21 citations and is from a poor quality or predatory journal.

## Citations

1. fuentes2024theroleof pages 10-12
2. alshehri2024cytochromecand pages 1-2
3. alshehri2024cytochromecand pages 3-5
4. alshehri2024cytochromecand pages 2-3
5. alshehri2024cytochromecand pages 11-11
6. alshehri2024cytochromecand pages 11-12
7. alshehri2024cytochromecand pages 8-8
8. https://doi.org/10.1016/j.jsps.2024.102194;
9. https://doi.org/10.1038/s42255-023-00904-w;
10. https://doi.org/10.3390/cells13070609;
11. https://doi.org/10.1016/j.jsps.2024.102194
12. https://doi.org/10.1038/s42255-023-00904-w
13. https://doi.org/10.3390/cells13070609
14. https://doi.org/10.1016/j.jsps.2024.102194,
15. https://doi.org/10.1038/s42255-023-00904-w,
16. https://doi.org/10.3390/cells13070609,